Objective To evaluate the quality of weight change (change in fat mass vs fat-free mass [FFM]), changes in cardiorespiratory fitness (CRF), and frequencies of metabolic risk factors in adolescent females with obesity who either lost or gained weight following lifestyle treatment.
T he long-standing position that weight loss is requisite for health improvements in obese adults has been challenged by a new paradigm that emphasizes health promotion and the adoption of healthy lifestyle behaviors over weight loss as a primary goal of interventions. 1 There is evidence that high levels of physical activity and/or cardiorespiratory fitness (CRF) attenuate the health risks associated with obesity in adults.
2,3 Short-and long-term improvements in body composition, CRF, and metabolic risk factors have been reported in adolescents, independent of weight loss. [4] [5] [6] [7] [8] [9] In the absence of weight loss, reduced frequencies of metabolic risk factors were coincident with the preservation of fat-free mass (FFM). 4, 5, 7, 8 Fat mass, however, did not increase in any of the aforementioned studies, and, importantly, the association between CRF and metabolic syndrome (MetS) appears to be mediated by adiposity. 10 The inability to distinguish the respective effects of body fatness, FFM, and CRF on MetS in obese adolescents precludes any clear interpretation as to which outcomes should be of most concern to clinicians.
It is unclear whether improvements in CRF and metabolic risk factors might be realized in adolescents whose body weight and fat mass increase during the treatment period. Because body weight is positively associated with metabolic disease risk in adolescents, 11 the risk of transitioning from the metabolically healthy to the metabolically unhealthy phenotype with weight gain is also of concern. Therefore, the aim of this study was to compare the quality of weight change (change in fat mass vs FFM) and changes in CRF and frequencies of metabolic risk factors in obese female adolescents who either lost weight or gained weight following participation in a multidisciplinary weight management program.
Methods
This study evaluated outcomes from obese adolescent females aged [11] [12] [13] [14] [15] [16] [17] [18] Peak oxygen consumption (TEENS) weight management program at Children's Hospital of Richmond at Virginia Commonwealth University. In order to enroll in the TEENS program, participants were between 11 and 17 years of age, had a body mass index (BMI) $85th percentile, weighed less than 182 kg (400 lbs), were free of any medical conditions that preclude weight loss, and had a primary care physician. In the current study, we chose to evaluate only females to control for the potential influence of sex on the outcome measures of interest. 12, 13 Given the challenges associated with attrition in this population 14 and the intent of this report to examine the influence of body weight and composition changes on cardiometabolic disease risk factors, only those who completed 6 months of the intervention were included in the analyses. All measures were recorded at baseline and after 6 months of program participation. Participants were retrospectively assigned to either the weight gain or weight loss group, depending on whether the 6-month weight change was positive or negative. The Virginia Commonwealth University Institutional Review Board approved all study procedures.
Body weight and height were measured by trained research staff using a digital scale and stadiometer to the nearest 0.1 kg and cm, respectively, and BMI was calculated as weight (kg) divided by height (m 2 ). BMI percentiles and Z-scores were determined using the 2000 Centers for Disease Control and Prevention growth charts. 15 Waist circumference was measured at the umbilicus and recorded to the nearest 0.1 cm using an anthropometric measuring tape. Pubertal status was classified by study physicians according to Tanner Staging. 16 Body composition was assessed by dual energy X-ray absorptiometry (Hologic D4500a/Discovery, Bedford, Massachusetts).
Resting blood pressure (BP) was assessed in triplicate with the participant in a seated position using an automated BP analyzer (Connex Vital Signs Monitor 6000 Series; Welch Allyn, Inc, Skaneateles Falls, New York). Elevated BP was defined as either systolic or diastolic BP >90th percentile for age, sex, and height. 17 Blood samples were collected from an antecubital vein after an overnight 12-hour fast. An automated clinical chemistry analyzer (Advia 1800 Chemistry System; Siemens Healthcare, Malvern, Pennsylvania) was used to measure total cholesterol, high-density lipoprotein (HDL), and triglycerides (TG). Glucose oxidase methodology was used to determine plasma glucose concentrations (2300 Stat Plus; YSI Life Sciences, Yellow Springs, Ohio). We also calculated the TG-to-HDL ratio (TG:HDL), as an elevated TG:HDL is associated with an increased risk of cardiometabolic disease in adolescents. 18, 19 Our classification of MetS in obese adolescents was contingent upon the participant exhibiting $3 of the following risk factors: moderate obesity (BMI >97th percentile for age and sex); TG $110 mg/dL; HDL-cholesterol #40 mg/dL; systolic or diastolic BP >90th percentile for age, sex, and height; and fasting glucose $100 mg/dL. 20 In the current study, BMI percentiles were converted to Z-scores and moderate obesity was defined as having a BMI Z-score >2.0 in order to standardize for age and sex. 21 After excluding BMI Z-score from the classification criteria, participants who were absent of any remaining MetS risk factors were identified as having the metabolically healthy obese (MHO) phenotype. 11, 22 Alternatively, participants with 1 MetS risk factor other than BMI Z-score >2.0 were considered metabolically unhealthy obese.
Peak oxygen consumption (VO 2peak ), a measure of CRF, was assessed using a metabolic cart (Vmax Encore; Sensormedics, Yorba Linda, California) during a graded treadmill test to volitional fatigue. The treadmill protocol consisted of an initial 4-minute stage at 2.5 mph, followed by a 2-minute stage at 3.0 mph. During subsequent 2-minute stages, speed was held constant, and grade was increased to 2%, 5%, 8%, 11%, 14%, and 17%. The final two stages were performed at a treadmill speed of 3.5 mph and grades of 17% and 20%. Heart rate was monitored throughout the test with a heart rate monitor (E600; Polar Electro, Lake Success, New York). To account for the influence of body weight and composition on CRF, VO 2peak was assessed in absolute terms (L O 2 $min
À1
) as well as in relation to body weight (mL O 2 $kg À1 min
) and FFM (mL O 2 $kg FFM À1 min À1 ). The TEENS weight management intervention has been described in detail elsewhere. 20, 23, 24 In brief, participants attended weekly nutritional education or behavioral support sessions and engaged in supervised aerobic and resistance training 3 days per week. The nutrition education sessions followed a standardized lesson plan 23 targeting high risk eating behaviors (eg, sugared beverage intake and breakfast consumption) associated with obesity. Behavioral support sessions (on alternating weeks as nutrition education sessions) used a behavior therapy approach to change, including goal-setting, stimulus control, social support, reinforcement, and examination of barriers and facilitators to program participation. The aerobic exercise component included 30 minutes of continuous activity performed at a heart rate $150 beats per minute, and the resistance training component included 2-3 sets of 12-15 repetitions of at least 10 resistance exercises. Two additional days of physical activity outside of the structured sessions were encouraged, and family YMCA memberships were provided to participants. After the first 3 months, participants were only required to attend supervised exercise sessions twice per week, although additional exercise sessions were encouraged.
Statistical Analyses
All statistical analyses were performed using SPSS v 22 for Windows (SPSS Inc, Chicago, Illinois). Paired samples t tests were used to determine if changes in continuous outcome variables were significant across all subjects and within the weight gain and weight loss groups. One-way ANOVA was used to determine whether 6-month changes in anthropometric, and VO 2peak measures differed between the weight gain and weight loss groups. Fisher exact tests were used to determine if pubertal status, race, and frequencies of MetS risk factors differed between weight change groups. The prevalence of MetS and metabolic risk factors was compared across time points using McNemar procedure. We also Vol. 166, No. 6 June 2015 evaluated whether the number of participants demonstrating the metabolically healthy and unhealthy phenotypes differed with respect to whether the 6-month weight change was positive or negative. All P values were 2-tailed and deemed statistically significant if P < .05.
Results
Baseline and 6-month data were available for 58 subjects. Forty-four (75.9%) participants were black, 10 (17.2%) white, 3 (5.2%) Hispanic, and 1 (1.7%) did not report race. Tanner Staging was available for 49 (84.5%) participants at baseline and 38 (65.5%) participants at 6 months. Only one participant was identified as prepubertal (Tanner Stage 1) at baseline. There were no anthropometric differences at baseline or in the change from baseline to 6 months between those with and without Tanner stage data (P > .05). Complete metabolic risk factor data were available for 57 (98.3%) of the 58 participants.
Of the 58 participants, 33 (57%) lost weight following the 6-month intervention (Table) . At baseline, body fat percentage was higher in the weight gain group compared with the weight loss group (43.8 AE 4.1% vs 40.5 AE 3.5, P = .002). No other between-group differences in anthropometrics, CRF, or metabolic risk factors were observed at baseline. In addition, ANOVA revealed no significant differences between weight loss and weight gain groups in race and Tanner Stage. At 6 months, height increased significantly in the weight gain group. However, all other differences between weight gain and weight loss groups at 6 months remained significant after controlling for change in height. Groups did not differ with respect to the number of exercise sessions attended during the intervention (P = .557). Therefore, all analyses are unadjusted unless otherwise noted.
Anthropometric and CRF measures, with the exception of FFM, were significantly improved in the weight loss group at 6 months (Table) . As expected, 6-month anthropometric changes were significantly different between the weight gain and weight loss groups (Table and Figure 1 ). Fat mass decreased by 4.5 AE 2.2 kg (P < .001) in the weight loss group, and, given the preservation of FFM, both weight (À4.5 AE 3.5 kg, P < .001) and body fat percentage (À3.0 AE 1.5%, P < .001) were also reduced. In contrast, weight increased by 4.5 AE 4.6 kg (P < .001) in the weight gain group, with approximately two-thirds of the observed weight gain attributed to gains in FFM. All measures of CRF were significantly increased in the weight loss group. In the weight gain group, absolute and relative VO 2peak, but not VO 2peak relative to FFM, were improved at 6 months. HDL-C, HDL-cholesterol; LDL-C, low-density lipoprotein-cholesterol; WC, waist circumference. *Significantly different from weight loss at the same time point (P < .05). †Significantly different from weight loss at the same time point (P < .01).
zChange from baseline to 6 months was significantly different from weight loss. xMetS was diagnosed if $3 of the following were present: elevated BP -systolic or diastolic BP $90th percentile for age, sex, and height; HDL-C -#40 mg/dL; TG -$110 mg/dL; fasting glucose -$100 mg/dL; BMI z-score ->2.0. {MHO phenotype was diagnosed if no other risk factor other than BMI z-score >2.0 was present.
THE JOURNAL OF PEDIATRICS www.jpeds.com
Vol. 166, No. 6 Figure 2 shows the percentage of all participants and within the weight gain and weight loss groups exhibiting 0, 1, 2, 3, and 4 cardiometabolic risk factors, as well as MetS and the MHO phenotype, before and after treatment. In the weight loss group, low-density lipoprotein cholesterol and fasting glucose decreased following treatment (P < .05), and no changes in cardiometabolic disease risk factors were observed in the weight gain group. The prevalence of MetS was relatively low at baseline and slightly decreased and increased in the weight loss (15.2% to 12.1%) or weight gain (12.5% to 20.8%) groups, respectively, with no difference between groups (P = .620). In contrast, prevalence of the MHO phenotype differed between weight change groups following treatment. The percentage of participants who were classified as MHO increased in both the weight loss (+18.2%) and weight gain (+8.3%) groups following 6 months of program participation. Alternatively, 16.7% of participants in the weight gain group compared with none in the weight loss group became metabolically unhealthy after exhibiting the MHO phenotype at baseline (P = .029).
Discussion
The weight loss and weight gain groups in the current study demonstrated increases in CRF; however, only the weight loss group improved body composition. Our finding that, of those who had the MHO phenotype at baseline, only participants in the weight gain group became metabolically unhealthy at 6 months supports previous reports that adiposity mediates the relation between CRF and MetS in adolescents. 10, 25 Although the degree of weight loss is a determinant of the magnitude of improvement in metabolic health, 26 reductions in risk factors were previously reported in adolescents who gained weight but lost fat mass. 5 In the current study, the transition from metabolically healthy to metabolically unhealthy obese in some participants who gained weight but none who lost weight suggests that body composition might also mediate any relation between improvements in FFM and MetS. However, the prevalence of the metabolically unhealthy phenotype was reduced in both weight change groups, even though obesity (BMI $95th percentile) was maintained in all but one participant. Clearly, further investigation of the relationships among body composition, CRF, and cardiometabolic health is needed in the obese adolescent population.
The generalizability of the current study's results is limited to predominately black females, and the lower prevalence of MetS in black compared with white 27 and female compared with male 11 adolescents may explain the relatively healthy metabolic profile observed in our participants. In turn, low baseline frequencies of individual risk factors reduced the likelihood of observing differences in improvements between weight loss and weight gain groups. In addition, we assigned participants to either the weight loss or weight gain groups Figure 1 . Body weight and composition changes in female adolescents who either lost or gained weight following participation in a 6-month behavioral weight loss intervention. *P < .05 Figure 2 . Percentages of A, all participants, B, those who lost weight, and C, those who gained weight with 0, 1, 2, 3, and 4 cardiometabolic risk factors, the MHO phenotype, and the MetS prior to and after 6 months of participation in a behavioral weight management program.
based on whether weight change was positive or negative, and the inclusion of participants with clinically negligible changes in body weight could have also limited our ability to detect differences in cardiometabolic risk factors and CRF. Lastly, conclusions cannot be drawn as to whether between-group differences in caloric intake or participant effort during the exercise sessions could further explain the group differences. However, each participant received the same nutritional education and participated in a standardized exercise training protocol. Further, exercise attendance did not differ between groups.
The wide variability in individual responses to weight management interventions often makes the evaluation of overall program efficacy challenging. After grouping our program participants according to whether weight was lost or gained, we observed dissimilar patterns of body composition change. Although the magnitude of improvement in metabolic health appeared to be larger with weight loss, obese adolescent females who gained body weight and fat mass still improved their CRF following participation in an intensive weight management program. Of note, two-thirds of the weight change in the weight gain group was attributed to increased FFM, with a concomitant preservation of body composition. It is currently unclear whether the health benefits associated with increases in FFM, without the loss of fat mass, are maintained over the long term. Further exploration of the associations among weight, body composition, fitness, and cardiometabolic risk factors is needed to establish doseresponse relationships among treatment strategies, weight loss outcomes, and health measurements to improve upon current treatment strategies. n program targeting urban, overweight adolescents: effects on physical fitness, physical activity, and blood lipid profiles. F ifty years ago, hydrocephalus was a dreadful diagnosis for children. Many were left untreated, and those fortunate enough to undergo placement of a ventriculoatrial shunt were disposed to septicemia, meningitis, shunt failure requiring frequent revisions, and, rarely, superior mediastinal venous obstruction or even pulmonary emboli.
As a byproduct of that era, Huttenlocher reported in The Journal the utility of an alternative therapy with acetazolamide in dosages from 40 to 100 mg/kg/d among a series of 15 children with slowly progressive hydrocephalus. His patients included 7 with congenital hydrocephalus, 3 with myelomingocele, and 4 post-meningitis; 7 were known to have communicating rather than obstructive hydrocephalus. Control, defined by complete cessation of abnormal head growth, was achieved in 8 children. Five of those controlled had communicating hydrocephalus, and 3 had aqueductal stenosis. Some of these children even demonstrated developmental and intellectual improvements.
Today, acetazolamide is rarely used for hydrocephalus. Ventriculoperitoneal shunting and more recently endoscopic third ventriculostomy have become commonplace and largely supplanted ventriculoatrial shunting and any medical treatment for hydrocephalus. Morbidity from shunting has dropped markedly, though not disappeared. Nevertheless, the use of acetazolamide is still a rarely useful "trick" in the "playbook" of the child neurologist or pediatric neurosurgeon.
After the passage of 50 years, acetazolamide can have a role treating slowly progressive communicating hydrocephalus or temporizing the symptoms of a child with obstructive hydrocephalus prior to more definitive treatment with a shunt. Acetazolamide is a carbonic anhydrase inhibitor; when used in moderate dosages of <25 mg/kg/d, it can lead to reduction of cerebrospinal fluid production. At higher dosages, the drug might paradoxically increase intracranial pressure via increased cerebral blood flow. A randomized trial of acetazolamide at 100 mg/kg/d plus furosemide
